[20200210]IF11250_美国食品和药物管理局对大麻二酚（CBD）消费品的监管.pdf

https:/crsreports.congress.gov Updated February 10, 2020FDA Regulation of Cannabidiol (CBD) Consumer ProductsCannabidiol (CBD) is promoted as treatment for a range of conditions, including anxiety, pain, inflammation, and post-traumatic stress disorderdespite limited scientific evidence to substantiate or disprove many of these claims. CBD is derived from the Cannabis sativa plant (commonly referred to as cannabis), which includes both marijuana and hemp. CBD and tetrahydrocannabinol (THC) are thought to be the most abundant cannabinoids in cannabis. CBD is considered to be nonpsychoactive and may be derived from either hemp or marijuana. THCa psychoactive compoundis found at high levels in marijuana and low levels in hemp. For additional information, see CRS Reports R46189 and R44742. Regulation of Cannabis: Overview Botanically, marijuana and hemp are from the same species of plant, Cannabis sativa, but from different varieties or cultivars. Marijuana and hemp have separate definitions in U.S. law and are subject to different statutory and regulatory requirements. Marijuana (as defined in statute) generally refers to the cultivated plant used as a psychotropic drug, either for m